FDA Drug GMP Warning Letters Increase 6%, Focus on Supply Chain and Sterility Assurance in FY 2011
This article was originally published in The Gold Sheet
Executive Summary
The number of drug GMP warning letters issued by FDA continued to climb in fiscal year 2011, with supply chain and sterility assurance issues dominating the agency’s attention. FDA is requesting a budget increase in FY 2013 to expand its inspectional presence abroad to better meet global supply chain threats, and agency officials are saying that failure to monitor contract manufacturers is a major problem shown in recent warning letters, but that failure to investigate out-of-specification results is still the No. 1 finding.
You may also be interested in...
Difficulty Identifying Experts Seen as a Factor in Poor Investigations
Pharmaceutical enterprises have become so complex that some sites with quality problems can’t find the root cause because they no longer know who their key experts are or where to find them, one industry expert says. Regardless of why they happen, inadequate investigations continue to be the most frequently cited GMP concern in FDA warning letters year after year.
Friend or Foe? The Role of Regulatory Relief in Drug Shortages
FDA’s Janet Woodcock argues that strong enforcement prevents drug shortages, dismissing allegations that crackdown under Hamburg triggered shortage crisis. There is more agreement, however, on the role of other factors such as group purchasing organizations, or GPOs, in the crisis.
Lack of Microbiological Controls Had Grave Consequences for Compounders
The current public health crisis stemming from microbiological contamination of sterile injectables at drug compounding pharmacies demonstrate the importance of having robust aseptic sterile processing programs, said an FDA official. Some problems at drug manufacturers were also highlighted showing inadequate microbiological controls.